PET measurements of neuroreceptor occupancy by typical and atypical neuroleptics

Journal of Nuclear Medicine

Volumn 37, Issue 7, 1996, Pages 1122-1127

  Goyer, Peter F ^a   Berridge, Marc S ^b   Morris, Evan D ^b   Semple, William E ^b   Compton Toth, Beth A ^b   Schulz, S Charles ^b   Wong, Dean F ^b   Miraldi, Flora ^b   Meltzer, Herbert Y ^b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

carbon 11 N methylspiperone; neuroreceptor occupancy; PET

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PERPHENAZINE; SEROTONIN 2A RECEPTOR; TRIFLUOPERAZINE; 3 METHYLSPIPERONE; 3-N-METHYLSPIPERONE; CARBON; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR; SPIPERONE;

ADULT; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; ISOTOPE LABELING; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR OCCUPANCY; TREATMENT OUTCOME; BASAL GANGLION; BIPOLAR DISORDER; BRAIN CORTEX; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; METABOLISM; SCHIZOPHRENIA; SCINTISCANNING;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BIPOLAR DISORDER; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; CEREBRAL CORTEX; CLOZAPINE; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SPIPERONE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029665861     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. 2 serotonin receptors in cerebral cortex. J Neurosci 1986;6:2941-2949.
2. 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci 1987;40:987-995.
3. Arnett CD, Fowler JS, Wolf AP, Shiue C-Y, McPherson DW. Fluorine-18-N-methylspiroperidol: the radioligand of choice for PETT studies of the dopamine receptor in human brain. Life Sci 1985;36:1359-1366.
4. 18F-N-methylspiroperidol binding in the baboon brain using PET. Synapse 1991;7:324-327.
5. Wagner HN, Burns HD, Dannals RF, et al. Imaging dopamine receptors in the human brain by positron tomography. Science 1983;221:1264-1266.
6. 18F]-N-methylspiroperidol and PET. J Nucl Med 1986;27:1878-1882.
7. Watson S, Girdlestone D. Receptor nomenclature supplement. Trends Pharmacol Sci 1993;14(suppl):21-72.
8. Wong DF, Wagner HN, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984;226:1393-1396.
9. Wong DF, Wagner HN, Coyle J, et al. Assessment of dopamine receptor blockade by neuroleptic drugs in the living human brain [Abstract]. J Nucl Med 1985;26(suppl): 52P-53P.
10. Gjedde A, Wong DF. Modeling neuroreceptor binding of radioligands in vivo. In: Frost JJ, Wagner HN, eds. Quantitative imaging: neuroreceptors, neurotransmitters and enzymes. New York: Raven Press; 1990:66.
11. Wong DF, Wagner HN, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-1563.
12. 76Br-bromolisuride. Br J Psychiatry 1991;158:346-350.
13. 18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol Psychiatry 1988;23:653-663.
14. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146: 905-908.
15. 18F-labelcd setoperone. J Neurochem 1990;54:1744-1754.
16. 18F) methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm Gen Sect 1991;86:163-173.
17. 2 receptor occupancy in clozapine-treated patients demonstrated by PET. Psychopharmacology 1993;110:365-367.
18. Meltzer HY. Clozapine: clinical advantages and biologic mechanisms. In: Schultz SC, Tamminga C, eds. Schizophrenia: a scientific focus. New York: Oxford Press; 1988:302-309.
19. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:S18-S27.
20. 11C]methyl) spiperone. Appl Radiat Isot 1986;37:433-434.
21. Semple WE, Goyer P, McCormick R, et al. Preliminary report: brain blood flow using PET in patients with post-traumatic stress disorder and substance-abuse histories. Biol Psychiatry 1993;34:115-118.
22. 2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology 1993;110:265-272.
23. Farde L, Nordstrom A-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992;160:30-33.
24. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-1449.
25. Nordstrom A-L, Farde L, Wiesel F-A, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic paticnls. Biol Psychiatry 1993;33:227-235.
26. Wong DF, Gjedde A, Wagner HN, et al. Quantification of neuroreceptors in the living human brain. II. inhibition studies of receptor density and affinity. J. Cereb Blood Flow Metab 1986;6:147-153.